Governance Positive

2026-08-10 19:33

- The 36th Annual General Meeting (AGM) was held on August 10, 2026; all resolutions passed with requisite majority. - A dividend of ₹30 per equity share (1,500%) for FY26 was recommended. - The company reported FY26 consolidated total income of ₹11,067 Cr (▲13.95% YoY) and Q1 FY27 consolidated income of ₹3,144 Cr.

Governance Positive

2026-08-10 19:26

- The 36th Annual General Meeting was held on August 10, 2026, where all resolutions were passed with requisite majority. - A dividend of ₹30 per equity share (1500%) for the financial year ended March 31, 2026, was declared. - For FY26, Consolidated Total Income increased to ₹11,067 crores (vs ₹9,712 crores in previous year), and Profit After Tax (PAT) stood at ₹2,568 crores. - For Q1 FY27, Consolidated Total Income was ₹3,144 crores, with Profit After Tax (PAT) of ₹902 crores. - The company highlighted ongoing capacity expansion, advancements in technology, and a positive outlook for the global pharmaceutical and CDMO markets, driven by specialty medicines and peptide therapeutics.

Financials Positive

2026-08-06 14:27

- Consolidated Total Income ₹3,144 Cr vs ₹2,529 Cr (▲24.3% YoY) - Consolidated PBT ₹1,180 Cr vs ₹733 Cr (▲61.0% YoY) - Consolidated PAT ₹902 Cr vs ₹545 Cr (▲65.5% YoY) - Management expects double-digit growth for the full year FY27. - Custom Synthesis contributed 60% and Generics 40% to revenue.

Business Update Neutral

2026-08-01 15:54

- Audio recording of Q1 FY27 earnings conference call held on August 01, 2026, at 14:00 Hrs. (IST) for the quarter ended June 30, 2026. - The recording has been uploaded on Divi's Laboratories Limited website under the Investors relations section.

Financials Positive

2026-08-01 11:40

- Consolidated Revenue ₹3080Cr vs ₹2410Cr (▲28% YoY) - EBITDA ₹1255Cr vs ₹729Cr (▲72% YoY) - PAT ₹902Cr vs ₹545Cr (▲66% YoY) - EBITDA Margin 41% vs 30% (▲1050bps)

Financials Positive

2026-08-01 11:37

- Consolidated Revenue ₹3080Cr vs ₹2410Cr (▲28% YoY) - EBITDA ₹1255Cr vs ₹729Cr (▲72% YoY) - PAT ₹902Cr vs ₹545Cr (▲66% YoY) - EBITDA Margin 40.8% vs 30.3% (▲1050bps) - Mr. B. Vara Prasad and Mr. J. Srinivasa Rao appointed as Senior Management Personnel (General Managers for Engineering Purchase and Raw Materials Purchase respectively) effective August 01, 2026.

Governance Neutral

2026-07-31 09:15

- Divi's Laboratories Limited announced the cessation of Mr. L. Ramesh Babu, Vice President (Procurement), and Mr. D. Madhu Babu, Vice President (Projects), as Senior Management Personnel. - Their cessation is effective from the close of business hours on July 31, 2026, due to retirement.

Business Update Neutral

2026-07-24 10:30

- Concall Schedule - Concall Date: August 01, 2026 - Concall Time: 14:00 hrs (IST)

Financials Neutral

2026-07-20 09:00

- Board meeting scheduled for August 01, 2026. - Purpose: To consider and approve unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. - Trading window to remain closed till August 03, 2026.

Governance Positive

2026-07-15 17:46

- The 36th Annual General Meeting (AGM) will be held on August 10, 2026, at 10:00 a.m. IST via Video Conferencing. - The Board recommended a dividend of ₹30/- per equity share (1,500%) for FY2025-26. - The Record Date for dividend is July 24, 2026, with payment on/from August 14, 2026. - Agenda includes adoption of financial statements and re-appointment of directors.

Business Update Positive

2026-07-15 17:42

- Filed Business Responsibility and Sustainability Report (BRSR) for FY 2025-26. - Reported ~13,500 TCO₂e GHG emissions reduced and ~1,59,500 KL water conserved. - Committed to net-zero GHG emissions by FY 2050 with specific environmental and safety targets. No regulatory issues.

Governance Neutral

2026-07-15 14:50

- 36th Annual General Meeting (AGM) of the Company is scheduled for Monday, August 10, 2026, at 10:00 a.m. (IST) via Video Conferencing (VC) / Other Audio-Visual Means (OAVM). - E-voting will commence on Thursday, August 06, 2026, at 9:00 a.m. (IST) and conclude on Sunday, August 09, 2026, at 5:00 p.m. (IST). - The Annual Report for the financial year 2025-26 has been made available to members and uploaded on the Company's website. - FY 2025-26 Financial Highlights: Total Income ₹10,894 crores, Profit After Tax ₹2,607 crores, Earnings Per Share ₹98.19. - The company invested over ₹15 billion in FY 2025-26 across its manufacturing network.

Routine Neutral

2026-06-30 10:56

- Trading Window for dealing in company securities will close from July 01, 2026. - It will remain closed until 48 hours after the declaration of unaudited financial results for the quarter ended June 30, 2026. - The date of the Board meeting for results will be intimated in due course.

Routine Neutral

2026-06-11 09:09

- Divi's Labs issued communication on TDS for FY25-26 dividend. - Board recommended ₹30/share (1500%) dividend on May 23, 2026. - Record date: July 24, 2026. Payment after August 10, 2026, AGM approval. - Shareholders must submit tax documents by July 24, 2026.

Business Update Positive

2026-05-29 10:32

Divi's Laboratories reported strong Q4 and FY26 performance. Management anticipates double-digit revenue growth for the future, with margins expected to remain stable despite competitive pricing and raw material cost pressures. The company capitalized ₹2,500 crores in FY26 (₹800 crores in Q4) and has ₹2,113 crores in capital work in progress, with revenue from capex expected within 2 years. Supply chain disruptions and increased freight costs due to geopolitical tensions were successfully managed, ensuring supply reliability. Growth drivers include a strong project pipeline in custom synthesis, deepening capabilities in peptides with validated fragments, and commercial sales in iodine-based contrast media. Exports constitute 89% of revenue, benefiting from currency depreciation. Divi's aims to be a leading global player in the peptide segment.

Financials Positive

2026-05-25 08:57

Consolidated Revenue ₹2831Cr vs ₹2585Cr (▲10% YoY), EBITDA ₹934Cr vs ₹886Cr (▲5% YoY), PAT ₹751Cr vs ₹662Cr (▲13% YoY). EBITDA Margin 33% vs 34% (▼128bps). The company also recommended a final dividend of ₹30/- per equity share for FY 2025-26.

Business Update Neutral

2026-05-23 18:31

Divi's Laboratories Limited announced the upload of the audio recording for its Q4 FY26 earnings conference call, held on May 23, 2026, at 14:30 Hrs. (IST), to the Investors Relations section of their website.

Financials Positive

2026-05-23 12:58

Consolidated Revenue ₹2,831Cr vs ₹2,585Cr (▲9.5% YoY), EBITDA ₹1,089Cr vs ₹972Cr (▲12.0% YoY), PAT ₹751Cr vs ₹662Cr (▲13.4% YoY). EBITDA Margin 38.5% vs 37.6% (▲90bps). A final dividend of ₹30/- per equity share was recommended for the financial year 2025-26, subject to shareholder approval.

Financials Positive

2026-05-23 12:21

Divi's Laboratories Limited announced its Consolidated Q4 FY2026 results. Consolidated Revenue was ₹2,831Cr vs ₹2,585Cr (▲10% YoY), EBITDA was ₹934Cr vs ₹886Cr (▲5% YoY), and PAT was ₹751Cr vs ₹662Cr (▲13% YoY). EBITDA Margin was 33% vs 34% (▼128bps). The company also recommended a final dividend of ₹30/- per equity share for FY2025-26.

Financials Positive

2026-05-23 12:13

Divi's Laboratories Limited reported Consolidated Revenue of ₹2,831 Cr vs ₹2,585 Cr (▲9.5% YoY), EBITDA of ₹934 Cr vs ₹886 Cr (▲5.4% YoY), and PAT of ₹751 Cr vs ₹662 Cr (▲13.4% YoY) for the quarter ended March 31, 2026. EBITDA Margin was 33.0% vs 34.3% (▼130bps). The Board also recommended a final dividend of ₹30/- per equity share for FY 2025-26.

Financials Neutral

2026-05-15 19:11

Divi's Laboratories Limited announced that its audited financial results for the quarter and year ended March 31, 2026 (Q4FY26), will be released on May 23, 2026. Following the release, the company will host an earnings conference call on the same day at 14:30 hrs (IST) to discuss its financial performance.

Financials Neutral

2026-05-14 12:11

Divi's Laboratories Limited announced that its Board of Directors will meet on May 23, 2026, to consider and approve the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The board will also consider recommending a dividend for the financial year 2025-26. The trading window for dealing in securities of the company will remain closed until May 25, 2026.

Routine Neutral

2026-03-31 10:03

Divi's Laboratories Limited announced the closure of its trading window from April 01, 2026, until 48 hours after the declaration of audited financial results for the quarter and financial year ended March 31, 2026. The Board meeting date will be intimated subsequently.

Business Update Negative

2026-03-21 16:18

CRITICAL RED FLAG DETECTED

Divi's Laboratories received a Draft Order from the Income Tax Authority for FY2022-23, proposing additions/disallowances of ₹570.51 crores related to Transfer Pricing and corporate tax adjustments, potentially leading to additional tax liability and penalty. The company plans to appeal.

Business Update Positive

2026-02-14 15:20

Divi's Laboratories submitted the transcript of its Q3FY2026 earnings conference call for the quarter and nine months ended December 31, 2025. Key updates included stable performance in Generics, healthy performance in Nutraceuticals, and a successful FDA inspection. An exceptional item of ₹74 crore was reported due to new labor codes.

Routine Neutral

2026-02-12 12:52

New Filing detected. See link for details.

Business Update Neutral

2026-02-11 17:28

Divi's Laboratories Limited announced the audio recording of its Q3FY26 earnings conference call, held on February 11, 2026, for the quarter ended December 31, 2025, has been uploaded on its website.

Routine Neutral

2026-02-11 12:40

New Filing detected. See link for details.

532488

Divis Laboratories Ltd

Price Chart

Filing History

Unlock Full History